FLGT News and Press, Fulgent Genetics Inc. From 02/28/25

Full Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 Fulgent Genetic...

National American University Holdings Inc (NAUH) is expected to report for Q2 2025 Chart Industries Inc. (GTLS) is expected to report $3.19 for Q4 2024 Rapid Micro Biosystems Inc. (RPID) is expected to report $-0.24 for Q4 2024 Basf SE ADR (BASFY) is expected to report $0.11 for Q4 20...

2025-02-27 11:22:03 ET More on Fulgent Genetics Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade) Seeking Alpha’s Quant Rating on Fulgent Genetics Historical earnings dat...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financ...

2025-01-25 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-01-04 13:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...